Wave Life Sciences Ltd.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company that designs, develops and commercializes stereopure ribonucleic acid (RNA) medicines for genetically defined diseases utilizing its proprietary PRISM platform; the platform combines multiple RNA-targeting modalities including RNA editing via AIMer technology, antisense silencing, and RNA interference with chemistry innovation and human genetics insights to create differentiated therapeutics. Core programs target alpha-1 antitrypsin deficiency (AATD) with WVE-006, a GalNAc-conjugated RNA editing oligonucleotide licensed exclusively to GSK; obesity with WVE-007, a GalNAc-siRNA targeting INHBE that demonstrated up to 85% Activin E reductions in the INLIGHT trial supporting potential once- or twice-yearly dosing for fat loss and muscle preservation; Duchenne muscular dystrophy (DMD) with WVE-N531, an exon-skipping oligonucleotide advancing toward a 2026 New Drug Application filing; and Huntington's disease (HD) with WVE-003, which received supportive FDA feedback including orphan drug designation. The company operates primarily in the genetic medicines industry serving patients with rare and prevalent disorders such as AATD, DMD, HD and obesity through wholly owned and partnered programs. Founded in 2012 and headquartered in Singapore with key research and development operations in Cambridge, Massachusetts, Wave maintains a UK subsidiary focused on pharmaceutical manufacturing. Recent developments include positive third-quarter 2025 clinical data for WVE-007 and WVE-006 validating RNA editing and RNAi capabilities; GSK's acquisition of additional shares worth $22.3 million in September 2024 increasing its ownership; termination of the Takeda collaboration in October 2024 allowing Wave to regain full control of its HD program; preclinical advancements supporting WVE-007 as monotherapy, GLP-1 add-on or maintenance therapy; and a cash position extending runway into 2027.
Company News
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
WAVE Life Sciences (NASDAQ:WVE) Sets New 1-Year Low – Here’s Why
Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)
WAVE Life Sciences (NASDAQ:WVE) Shares Climb 9.3% – Here’s What Happened
WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up – Time to Buy?
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)
These beaten-down stocks could bounce back in January, if history is any guide
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences to Present at Upcoming Investor Conferences
WAVE Life Sciences Q2 Earnings Call Highlights